NFIX and cancer: To explore the expression of NFIX, TIMER 2.0 database analysis (Figure 1A) revealed that NFIX was downregulated in many cancers, including bladder urothelial bladder carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma, endocervical adenocarcinoma (CESC), head and neck squamous cell carcinoma (HNSC), kidney renal papillary cell carcinoma (KIRP), LUAD, LUSC, stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and uterine corpus endometrial carcinoma (UCSC).